Clinical Trials Logo

Clinical Trial Summary

This study is designed to learn more about overall tau burden in the brain of patients with Primary Progressive Aphasia (PPA) and Frontotemporal Dementia.


Clinical Trial Description

Primary progressive aphasia (PPA) is an umbrella term that encompasses a group of neurodegenerative syndromes characterized by varying combinations of progressive speech and language problems. Three clinical variants of PPA have been described and are well recognized: the agrammatic variant characterized by grammatical errors in speech and writing and typically associated with phonetic errors in speech; the semantic variant characterized by poor naming from loss of knowledge about the meaning of words; and the logopenic variant characterized by word retrieval problems and poor sentence repetition from impairment of working memory and phonemic errors. Pathological studies of PPA patients that died with postmortem examination of their brains have demonstrated that PPA is associated with a number of different abnormal cellular proteins that do not have perfect associations with the three PPA variants. One such protein is the microtubule associated protein, tau, which is the most common abnormal protein found in the brains of patients with PPA. Tau is an important protein that has been linked to the neurodegenerative process in many diseases. No neuroimaging studies have investigated tau deposition in PPA and hence the binding characteristics of AV-1451 (the Tau binding drug used in this study) in PPA are unknown. Understanding the binding characteristics of AV-1451 is crucial to help determine whether it can serve as a biomarker for tau deposition in the brains of patients with PPA. FTD or Frontotemporal Dementias, including bvFTD, will also be included in this study. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT02736695
Study type Interventional
Source Mayo Clinic
Contact Sarah M Boland, CCRP
Phone 507-284-3863
Email boland.sarah@mayo.edu
Status Recruiting
Phase N/A
Start date July 2016
Completion date June 1, 2030

See also
  Status Clinical Trial Phase
Suspended NCT04290988 - Circuitry Assessment and Reinforcement Training Effects on Recovery N/A
Recruiting NCT04957537 - Semantic Rehabilitation for Patients With Primary Progressive Semantic Aphasia N/A
Completed NCT04045990 - Network Modulation in Alzheimer's Disease N/A
Recruiting NCT05443633 - Enhancing Language Function in Aphasia N/A
Completed NCT05860647 - Transmagnetic Stimulation Pilot in Primary Progressive Aphasia N/A
Recruiting NCT03887481 - Targeting Language-specific and Executive-control Networks With Transcranial Direct Current Stimulation in Logopenic Variant PPA N/A
Completed NCT03728582 - Rehabilitating and Decelerating Language Loss in Primary Progressive Aphasia With tDCS Plus Language Therapy N/A
Completed NCT01465360 - Performance of AclarusDx™, a Blood-Based Transcriptomic Test for AD, in US Patients Newly Referred to a Memory Center N/A
Completed NCT02541097 - Preventing Language Decline in Dementia N/A
Recruiting NCT00537004 - Language in Primary Progressive Aphasia
Recruiting NCT05741853 - Cognitive Reserve and Response to Speech-Language Intervention in Bilingual Speakers With Primary Progressive Aphasia N/A
Active, not recruiting NCT05742698 - Nabilone for Agitation in Frontotemporal Dementia Phase 2
Completed NCT02439853 - Communication Bridge Speech Therapy Research Study N/A
Completed NCT01623284 - PiB PET Scanning in Speech and Language Based Dementias Phase 1
Completed NCT04726527 - Clinical Evaluation of Florbetapir in Primary Progressive Aphasia
Completed NCT03076671 - More Than a Movement Disorder: Applying Palliative Care to Parkinson's Disease N/A
Completed NCT05537688 - Identification of Graphic Markers of Neurocognitive Disorders (MG)
Completed NCT05525377 - Better Living With Non-memory-led Dementia N/A
Not yet recruiting NCT06191198 - Communication Bridge 3 Study Phase 2
Completed NCT02928848 - Transcranial Direct Current Stimulation for Primary Progressive Aphasia N/A